Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S. Nekeman
Pdb81 - Dapagliflozin Is Cost-Effective Compared to DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)
Cost-Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors as an Add-On to Metformin in the Treatment of Type 2 Diabetes Mellitus From a UK Healthcare System Perspective
BMC Health Services Research
Health Policy
Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Need for Streamlined Use of DPP-4 Inhibitors in the Treatment of Type 2 Diabetes
Cardiovascular Diabetology
Internal Medicine
Cardiology
Endocrinology
Cardiovascular Medicine
Metabolism
Diabetes
Dapagliflozin: A New Adjunct in the Treatment of Type 2 Diabetes Mellitus
International Journal of Basic & Clinical Pharmacology
Use of DPP-4 Inhibitors in Type 2 Diabetes: Focus on Sitagliptin
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal Medicine
Pharmacology
Systematic Literature Review of DPP-4 Inhibitors in Patients With Type 2 Diabetes Mellitus and Renal Impairment
Diabetes Therapy
Internal Medicine
Endocrinology
Metabolism
Diabetes
Emerging DPP-4 Inhibitors: Focus on Linagliptin for Type 2 Diabetes
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal Medicine
Pharmacology
Prescription of DPP-4 Inhibitors to Type 2 Diabetes Mellitus Patients With Renal Impairment: A UK Primary Care Experience
Clinical Therapeutics
Pharmacology
